entertainment -WSS

entertainment

author：leisure time 2025-10-02 17:22:34 - browse：92

It’s no secret that biotech industry funding has fallen from its Covid highs. But with just a few months left in the year, it’s on track to hit lows that predate the pandemic.

New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly. So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013. For comparison, there were roughly 2,122 financing deals made last year.

If dealmaking remains consistent for the rest of the year, it would put this year on par with the number of deals made in 2017.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： CRISPR base editing slashes cholesterol levels in monkeys

WSS

HHS's proposed rule does nothing to address the climate crisis

Warren pushes Witty on UnitedHealth's control over physicians

IVG is promising — but it won’t replace IVF quite yet

Stop Congress from blocking public access to science

With Roe v Wade overturned, abortion providers work to adapt

Class action alleges UnitedHealth concealed DOJ probe

focus

entertainment

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

As billionaires fund anti

Tori Bowie and the unacceptable rates of Black maternal death

How a small hospital in rural Puerto Rico survived Hurricane Maria

State Dept. review finds Biden bears some blame for Afghanistan failures

Lawmakers grill UnitedHealth CEO on Change cyberattack

Medical leaders decry Supreme Court decision on affirmative action

Lawsuit highlights wrinkle for disputes over surprise medical bills

Virginia high school admissions case could be legal follow

Health insurers' Q3 question: how much care are people getting?

focus

The effects of a landmark ruling on DNA ownership are becoming clearer

The stability of $0 premiums in Medicare Advantage

WHO recommends second malaria vaccine

Crowdfunding for medical bills sidesteps core problem, author says

AI for drug discovery: Experts on separating hype from reality

PBM executives asked to testify by House panel

focus

leisure time

focus

explore